Fitchburg, WI, United States of America

Thomas K Zielinski


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Thomas K. Zielinski: Innovator in Genetically Engineered G-alpha Proteins

Introduction

Thomas K. Zielinski is a prominent inventor based in Fitchburg, WI (US). He has made significant contributions to the field of biochemistry, particularly in the development of genetically engineered G-alpha proteins. His work has the potential to advance drug discovery and improve pharmacotherapies for various central nervous system disorders.

Latest Patents

Zielinski holds a patent for "Genetically engineered G-alpha proteins and uses thereof." This invention relates to novel engineered Ga proteins and assay methods that utilize these proteins to enhance drug discovery. The engineered Ga proteins described in the patent contain alterations of at least one, and preferably two or more, amino acid residues that are highly conserved among all four subfamilies of Ga proteins. A notable engineered protein disclosed in the patent is a double mutant, Gαπ R178M A326S. This specific combination of mutations yields an unexpectedly amplified effect on Ga function, both in terms of GTPase activity and GDP dissociation. The synergistic effect of these mutations may significantly influence the examination of GPCR signaling pathways, particularly in developing new pharmacotherapies for disorders such as Parkinson's disease.

Career Highlights

Zielinski is currently associated with Bellbrook Labs, LLC, where he continues to innovate and contribute to the field of drug discovery. His work at Bellbrook Labs focuses on advancing the understanding of G-alpha proteins and their applications in pharmacology.

Collaborations

One of Zielinski's notable collaborators is Robert G. Lowery. Together, they have worked on projects that aim to enhance the understanding of G-alpha proteins and their potential therapeutic applications.

Conclusion

Thomas K. Zielinski's innovative work in genetically engineered G-alpha proteins represents a significant advancement in drug discovery. His contributions have the potential to lead to new treatments for central nervous system disorders, showcasing the importance of innovation in the field of biochemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…